<DOC>
	<DOCNO>NCT02343939</DOCNO>
	<brief_summary>This study evaluate efficacy , safety , tolerability , pharmacodynamics entospletinib ( GS-9973 ) administer monotherapy combination chemotherapy adult acute myeloid leukemia ( AML ) .</brief_summary>
	<brief_title>Entospletinib Monotherapy Combination With Chemotherapy Adults With Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Key Adults AML need treatment ( except individual acute promyelocytic leukemia M3 ) Group A : Individuals &gt; 18 year age previously untreated AML able receive cytarabine amd daunorubicin ( 7+3 ) chemotherapy determine treat physician Group B : Individuals &gt; 70 year age previously untreated AML individual &lt; 70 year age previously untreated AML refuse unable receive cytarabine determine treat physician Group C : Individuals &gt; 18 year age relapse refractory AML WHO criteria individual previously untreated AML would meet eligibility criterion Groups A B refuse unable receive chemotherapy determine treat physician Key Known active central nervous system leptomeningeal lymphoma NOTE : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>